Noach, You said nothing. All those "indications" were fully understood by the pros before AK pulled one of his pro-grade stunts and dumped T-stock into Israel.
You didn't get played---you wanted to feel like a player--and BTX obliged you.
Every time I engaged you on the only actual issues for a common stock--time to net cash flow per share--you ran off in some new direction. And all of it came down to "stem cells = Mikey"--which has been the long con since BTX did a massive d/e swap to keep from closing the doors, and Mikey moved from the BOD to CEO slot--even though he had proven at GERN and ACTC that he couldn't deliver.
" The way to invest in Biotime is to just buy what you're comfortable with and forget about it. The long haul is all that matters." That makes BTX stick the same as tickets in a charity raffle. WHich it is--only the charity is to benefit the insiders and cronies.
Your detailed point is that you consistently refused to do actual DD on this dog, and fell for the "stem cells=BTX" nonsense being pumped since 2008.
Once you figured out that this dog, like any common stock, is about time to net positive cash flow, you intelligently got out--while trying to pretend other wise.
Your whole nonsense about "good entry point" is no different than what I have been saying here for years--if you like this dog trade into accumulation, and don't trust mgt until your net basis is close to theirs.
The only thing more laughable than yocur posturing is your turning down of an easy $50K---show I have been short this dog--or any other-- at any time except as covered calls, and the $50k is yours.
Since you can't, you're now proving to everyone here what a lying little piece of poser game boy you were since arrival.
Noach, So, after all the nonsense, you did some basic math and realised there's no revenue coming before the next major round of dilution....
Year-end portfolio adjustment is over, and there are NO F/A reasons to but this dog, and depending on net basis, no reasons to sell. On a T/A basis, it's in a bear rally about which no one cares except the Koolade drinkers.
That''s not theft. It's just an indication of how NOT special or cutting edge BTX actually is.
Nobody has to imagine the i/p value: they can take Biotime's word for it: $34,906,000. It's right there in the 10Q. And that's Biotime's necessarily optimistic opinion.
At 5X the i/p, this dog settles at $1.50. At 2x, under a buck.
Right now its principle asset is cash on hand--from dilution--which will run out around the end of 2016--at which point another round of dilution that will be tuned to make sure AK, Neal and Garfies lose nothing.
Right. It's a manipulated SC.
Currently it seems to be getting support at 3 3/4 from year-end short covering with plenty of sellers available.
So you are now running away from the numbers on AMD....
Excellent demo that you know they don;t add up.
Hi there lying #$%$. Great job of showing you have no facts to back your "long" argument. And also prove you know nothing at all about me. ..Bujt think it's safer to lie about me than try to show this dog is worth 2 bux.
So...$ to BTX lower than I would posit, and cost to approval at the high range.
Number of patients per year?
Note to passersby--- this is how it's done. NOT the cultist koolade of the "longs" around here.
DD the environment, run the numbers... and then, in the case of this dog, figure the o/s by the time things are $1k GAAP net positive cash flow. Take your favorite inverse multiple, from 12 to 26... and then how much of the alleged future cash flow is priced in right now is obvious.
And anything else is pure chicken poop bingo and the crushing of retail road kill by the pros.
True enough. So let's go to a straight F/A--which puts this dog at around round either 3/4 or zero. (Book or free cash flow.) It's a story stock. Ain't nothing wrong with that--when the story can stand up to DD. This dog stopped doing that at a buck-fifty...and has now begun the long march to chicken poop bingo---which changed its name to "Ocata" after destroying all of the original retail holders....
I'll be more generous than that: $15k an eye and BTX gets $2500--of which 40% is COG, for $1500 an eye.
and 5% of Medicare patients with the condition. For 10 years--since the tech is already getting obsoleted.
Now then the question becomes is it $30mm or $60mm to get to FDA approval? And how much dilution to get there? How many years from now?
" they can issue secondaries and cause dilution." Yes---which is the only point to spinning off a non-profitable "subsidiary" that was nothing but an accounting trick .
Noach, You are doing a brilliant job of showing why BTX dumped all those T-shares into Israel---a new dish of potent retail road kill .
So, now that it's been proven you know nothing about the field other than what B TX cronies tell you, back to "Renevia."--and how many years away is $1k GAAP positive revenue.
"For AMD treatment alone: $50,000 per eye!" According to whom? And agaiun--what % of that would go to BTX?
From there we can work towards how many a year, and COG including R&D, regulatory, etc.
And, hehe, what's the cost from today to FDA approval? REmember, a condtion with 35 million patients is not orphan....so the runaround that chicken poop bingo tried---Starsgart---is off the table.
" Let's say the cost basis of their stock is 80,000,000 " Let's say it's $3 billion. Whatever AK's people can make it be.. It's an accounting trick.
And it's being done to ensure that an y actual GAAP net revenues this dog ever has accrue to insiders and cronies at the expense of retail cannon fodder--as shown by change in o/s and shareholder deficit.
Thumb up for trying. But " will be worth hundreds of billions of dollars. " is nonsense. Of those "300 million" how many can pay $20, let alone $20K?
Show me a nice 200 words of whatr I would have demanded from a high school intern as to how many dollars per treatrment go back to BTX--NOT the gross expense charged by the delivering agency--on how many people per year who can get the treatment, and what will be the COG and the amortision of the R&D and regulatory costs, and then we can talk about whether it's priced in.
Given how BTX itself values its IP, the difference between $2 and the present prices is priced in future revs.
BTW-- notice how Noach runs from discussing "Renevia" revenues against cost to mkt....
That might be nice for CUR--and would be even nicer if NSI189 had anything to do with stem cells.
Benzylpiperizine and aminiopyridine have been around 40 years or more.
And that announcement is actually more than a year old.
Great job of showing smoke&mirrors as the basis for BTX.